NVP-QAV-572

Cat. No.: HY-16355

CAS No.: 957209-68-6

Molecular Formula: $C_{17}H_{19}F_2N_7O_3S_2$

Molecular Weight: 471.5

Target: PI3K

Pathway: PI3K/Akt/mTOR

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (265.11 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1209 mL	10.6045 mL	21.2089 mL
	5 mM	0.4242 mL	2.1209 mL	4.2418 mL
	10 mM	0.2121 mL	1.0604 mL	2.1209 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

NVP-QAV-572 is a PI3K inhibitor extracted from patent US7998990B2, Compound Example 8, has an IC_{50} of 10 nM.

IC_{50} & Target

PI3K
10 nM (IC_{50})

In Vitro

NVP-QAV-572 (Example 8) is useful in the treatment of conditions which are mediated by the activation of the Pi3 kinase enzymes, particularly inflammatory or allergic conditions[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Emma Budd, et al. 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors. US 7998990 B2.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA